The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options – an overview
B. Solomon & J.-C. Soria

The role of the ALK receptor in cancer biology
B. Hallberg & R. H. Palmer

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
K. M. Kerr & F. López-Ríos

ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology

Crizotinib: from discovery to accelerated development to front-line treatment
F. Blackhall & F. Cappuzzo

Crizotinib resistance: implications for therapeutic strategies
I. Dagogo-Jack & A. T. Shaw